You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductISOX INACT (Cat. No. 5808) has been withdrawn from sale for commercial reasons.
Biological Activity for ISOX INACT
ISOX INACT is a negative control for PF CBP1. Exhibits negligible activity at CBP and BRD4.
Active Analog also available.
Sold for research purposes under agreement from Pfizer Inc.
Technical Data for ISOX INACT
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for ISOX INACT
References are publications that support the biological activity of the product.
Chekler et al (2015) Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem.Biol. 22 1588 PMID: 26670081
View Related Products by Product Action
Keywords: ISOX INACT, ISOX INACT supplier, ISOXINACT, negative, control, PFCBP1, bromodomains, CBP, BRD4, Bromodomains, 5808, Tocris Bioscience
Citations for ISOX INACT
Citations are publications that use Tocris products.
Currently there are no citations for ISOX INACT.
Reviews for ISOX INACT
There are currently no reviews for this product. Be the first to review ISOX INACT and earn rewards!
Have you used ISOX INACT?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.